Jazz Pharmaceuticals (NASDAQ: JAZZ) and VBI Vaccines (NASDAQ:VBIV) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.

Earnings and Valuation

This table compares Jazz Pharmaceuticals and VBI Vaccines’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Jazz Pharmaceuticals $1.49 billion 5.64 $396.83 million $6.07 23.06
VBI Vaccines $550,000.00 464.07 -$23.20 million N/A N/A

Jazz Pharmaceuticals has higher revenue and earnings than VBI Vaccines.

Risk & Volatility

Jazz Pharmaceuticals has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, VBI Vaccines has a beta of 3.93, suggesting that its share price is 293% more volatile than the S&P 500.

Institutional & Insider Ownership

91.3% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 21.0% of VBI Vaccines shares are owned by institutional investors. 4.3% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 34.1% of VBI Vaccines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings for Jazz Pharmaceuticals and VBI Vaccines, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jazz Pharmaceuticals 0 5 17 0 2.77
VBI Vaccines 0 0 3 0 3.00

Jazz Pharmaceuticals presently has a consensus price target of $182.95, indicating a potential upside of 30.68%. VBI Vaccines has a consensus price target of $10.50, indicating a potential upside of 162.50%. Given VBI Vaccines’ stronger consensus rating and higher probable upside, analysts plainly believe VBI Vaccines is more favorable than Jazz Pharmaceuticals.

Profitability

This table compares Jazz Pharmaceuticals and VBI Vaccines’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Jazz Pharmaceuticals 23.58% 22.92% 10.07%
VBI Vaccines -4,463.06% -49.17% -37.55%

Summary

Jazz Pharmaceuticals beats VBI Vaccines on 7 of the 12 factors compared between the two stocks.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).

About VBI Vaccines

VBI Vaccines Inc., formerly SciVac Therapeutics Inc., is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens. It is engaged in developing an experimental CMV vaccine using its eVLP vaccine platform. The vaccine is based on the CMV glycoprotein B antigen and is adjuvanted with aluminum phosphate. The eVLP vaccine technology allows for the expression of envelope glyco-proteins within a lipid-bilayer membrane of a VLP. It is developing a therapeutic vaccine candidate for glioblastoma multiforme (GBM). It is developing a vaccine to prevent respiratory syncytial virus (RSV) infection. It also offers Sci-B-Vac, which is a third-generation hepatitis B vaccine.

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.